EIF2AK3 and Parkinson disease: Increased levels of UPR activation and PERK-P and eIF2α-P have been described in the brains of Alzheimer disease, Parkinson disease, and prion disease patients (41, –, 45), and genetic polymorphisms in PERK predispose to the tauopathy progressive supranuclear palsy (46).